NVO•benzinga•
Ozempic/Wegovy Maker Maintains Q3 Sales Growth On Booming Demand
Summary
Novo Nordisk's Q3 2024 report highlights a 21% YoY sales increase with strong gains in GLP-1 diabetes and obesity drugs but falls short of analyst expectations.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on November 6, 2024 by benzinga